Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes

Posted on by

Nature Biotechnology
Volume 40 Issue 2, February 2022
https://www.nature.com/nbt/volumes/40/issues/2

 

Patents | 15 February 2022
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Additional changes could make the registries of drug patents published by the FDA, called the Orange and Purple Books, more useful and reduce barriers to effective competition from generic and biosimilar drugs.
Bryan S. Walsh, Jonathan J. Darrow, Aaron S. Kesselheim